MENU
ARVN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Arvinas (ARVN) Ownership - Who owns Arvinas?

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins... Show more

Industry: #Biotechnology

Profile

Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
445
Web
https://www.arvinas.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
524.08M
P/E Ratio
N/A
Total Cash
954.3M
Projected Growth
N/A
Total Debt
10.5M
Revenue
426.9M
Risk (Beta)
2.24
Dividend Yield
N/A
Total Cash/Share
13.07
Total Debt/Equity
N/A
Revenue/Share
5.92 USD as % of share price

Fundamentals

ARVN
Capitalization
524M
P/E Ratio
N/A
Risk (Beta)
2.24
Dividend Yield
N/A
Total Cash
954M
Total Cash/Share
13.07
Total Debt
10.5M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
5.92%
Revenue
427M
ROE
N/A
Book Value
660M
P/B Ratio
0.79
Cash Flow
N/A
Earnings
-0.66
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
100K
Current Ratio
4.58
Current Revenue Per Employee
439069.78
Dividends Per Share - Security
N/A
EBITDA
-89.3M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-4.21
Shares Held By Institutions
3.15B
Shares Outstanding - Current
73M
Total Liabilities
341M
Total Volume MTD
N/A
Value
1
Gain YTD
-62.546
View a ticker or compare two or three
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapies to degrade disease-causing proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
445
Web
https://www.arvinas.com